The real costs of the new Alzheimer's drug | Health
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for
Stay updated with breaking news from Libby Holman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for
To qualify for Leqembi, patients must undergo a PET scan that looks for amyloid plaques, the protein clumps that clog the brains of many Alzheimer’s patients.
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for
Although Leqembi can help treat Alzheimer's disease, there are risks, as well as cost and accessibility issues that may pose as concerns.